Posts tagged Massachusetts
What’s happening to generic drug prices? October 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw a lot of price increases this past month, but an overall decrease in annualized spending. As always, the details matter, and we’re here to provide them for you. For those that have followed previous 46brooklyn reports, there are several familiar drugs that experienced significant pricing movement this past month, so this piece will be a good trip down memory lane. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart.

Read More
Newly released CMS drug pricing data reveals continued generic drug pricing distortions

Last week, we were met with a delightful surprise as we were perusing through the CMS website and discovered an out-of-the-blue drug pricing data update just begging to be downloaded. The hidden treasure was the freshly-updated CMS State Utilization database, which provides quarterly drug pricing data that shows what state Medicaid programs are spending on prescription drugs, providing an excellent window into the price-setting practices of the prescription drug supply chain. This most recent CMS data update ended up filling in most of the Q3 2018 divots and extended the 2018 data to include large portions of the fourth quarter. We have updated all of our dashboards that rely on this dataset, rolling all of them forward to Q4 2018. We couldn't resist sneaking an extended peak at the data, and while we will offer more in-depth analyses soon, we wanted to give some of our initial takeaways.

Read More